A Poly(Lactic--Glycolic) Acid Nanovaccine Based on Chimeric Peptides from Different Proteins Induces Dendritic Cells Maturation and Promotes Peptide-Specific IFNγ-Producing CD8 T Cells Essential for the Protection against Experimental Visceral Leishmaniasis.

Visceral leishmaniasis, caused by (.) and protozoan parasites, can provoke overwhelming and protracted epidemics, with high case-fatality rates. An effective vaccine against the disease must rely on the generation of a strong and long-lasting T cell immunity, mediated by CD4 T and CD8 T cells. Multi-epitope peptide-based vaccine development is manifesting as the new era of vaccination strategies against infection. In this study, we designed chimeric peptides containing HLA-restricted epitopes from three immunogenic proteins (cysteine peptidase A, histone H1, and kinetoplastid membrane protein 11), in order to be encapsulated in poly(lactic--glycolic) acid nanoparticles with or without the adjuvant monophosphoryl lipid A (MPLA) or surface modification with an octapeptide targeting the tumor necrosis factor receptor II. We aimed to construct differentially functionalized peptide-based nanovaccine candidates and investigate their capacity to stimulate the immunomodulatory properties of dendritic cells (DCs), which are critical regulators of adaptive immunity generated upon vaccination. According to our results, DCs stimulation with the peptide-based nanovaccine candidates with MPLA incorporation or surface modification induced an enhanced maturation profile with prominent IL-12 production, promoting allogeneic T cell proliferation and intracellular production of IFNγ by CD4 and CD8 T cell subsets. In addition, DCs stimulated with the peptide-based nanovaccine candidate with MPLA incorporation exhibited a robust transcriptional activation, characterized by upregulated genes indicative of vaccine-driven DCs differentiation toward type 1 phenotype. Immunization of HLA A2.1 transgenic mice with this peptide-based nanovaccine candidate induced peptide-specific IFNγ-producing CD8 T cells and conferred significant protection against infection. Concluding, our findings supported that encapsulation of more than one chimeric multi-epitope peptides from different immunogenic proteins in a proper biocompatible delivery system with the right adjuvant is considered as an improved promising approach for the development of a vaccine against VL.